Globus Medical, Inc. (NYSE: GMED) announced preliminary unaudited sales results for the fourth quarter and full year ended December 31, 2025.
The company anticipates Q4 2025 sales of approximately $823.2 million, a 25.2% increase over Q4 2024.
Full year 2025 sales are expected to be around $2.936 billion, showing a 16.5% increase from the previous year.
Strong Finish to 2025
Preliminary Q4 results show strong momentum and revenue growth, with a focus on innovation and operational excellence.
Market Growth and Acquisitions
The company demonstrated above-market growth and successful integration of recent acquisitions, driving revenue growth.
Financial Guidance for 2026
Globus Medical sets revenue guidance range of $3.18 billion to $3.22 billion and non-GAAP earnings per share range of $4.30 to $4.40 for 2026.
- Globus Medical's performance in Q4 2025 exceeded expectations with substantial revenue growth.
- The successful integration of acquisitions and focus on innovation position the company for sustained growth in 2026.
With strong Q4 results and promising full-year sales, Globus Medical is on a positive trajectory for continued success in 2026.